The expression of angiopoietins and their receptor tie-2 in human prostate carcinoma

Anticancer Research

Volumn 20, Issue 6 D, 2000, Pages 5217-5220

  Wurmbach, J H ^a   Hammerer, P ^a   Sevinc, S ^a   Huland, H ^a   Ergun S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angio poietin 2; Angiogenesis; Angiopoietin 1; Prostate cancer; Tie 2

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; GROWTH FACTOR RECEPTOR;

ANGIOGENESIS; CAPILLARY; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CARCINOMA, INTRADUCTAL, NONINFILTRATING; HUMANS; IMMUNOASSAY; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2;

EID: 0034451980     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Signaling vascular morphogenesis and maintenance
2. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
3. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during, embryonic angiogenesis
4. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker oftumor angiogenesis
5. Angiopoietin-1 and its receptor tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells
6. Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors
7. Angiopoietin-1 is an apoptosis survival factor for endothelial cells
8. Increased vascularization in mice overexpressing angiopoietin-1
9. Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells
10. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells
11. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia
12. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells
13. Angiogenic peptides in prostatic disease
14. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
15. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
16. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts
17. Vascular endothelial growth factor is up- regulated in vitro and in vivo by androgens
18. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
19. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma
20. Angiogenesis: Prognostic marker in prostatic cancer
21. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome
22. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies
23. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
24. Vascular endothelial growth factor and its receptors in normal human testicular tissue
25. Combination of the peroxidase antiperoxidase (PAP)- and avidin-biotin- peroxidase complex (ABC)techniques: An amplification alternative in immunocytochemical staining
26. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
27. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
28. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
29. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family
30. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes